What is APGE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 10.22B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for APGE?

P/E (TTM) is n/a and 52-week range is $51.80 to $135.09 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s APGE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for APGE?

The company profile lists net income (TTM) near -$328M, EPS (TTM) near -$4.34 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Apogee Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Waltham, Massachusetts, US, 75.7M shares outstanding, ISIN US03770N1019 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Apogee Therapeutics Inc

$APGE

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Apogee Therapeutics, Inc. is a clinical stage biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 261,000 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.

Employees

261,000

Website

apogeetherapeutics.com/

IPO

2023-07-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)